文献速递创伤与烧伤心脑血管急症

轻型创伤性脑损伤诊断性血液生物标志物与神经影像学表现的关联

Associations Between Diagnostic Blood-Based Biomarkers and Neuroimaging Findings in Mild Traumatic Brain Injury.
PubMed 文献 · Ann Emerg Med · 2026-10-27
一句话结论在疑似mTBI成人中,GFAP/UCH-L1联合血浆检测高敏低特,阴性预测值0.95,可作CT前排除颅内损伤的初筛工具,但需多中心验证。

单中心验证研究纳入104例疑似轻型创伤性脑损伤并接受头部CT的成人患者,伤后12小时内采血检测GFAP/UCH-L1。联合检测预测CT颅内损伤的敏感性0.91(95%CI 0.59-1.00),特异性0.22(95%CI 0.14-0.31),阳性预测值0.12,阴性预测值0.95。假阳性者年龄偏大(中位72岁 vs 58.5岁)。生物标志物检测周转时间比头部CT快约2小时。作者认为可作CT前排除工具,但需大型多中心研究明确对急诊资源利用和费用的影响。

要点

  • 在104例疑似mTBI成人中,GFAP/UCH-L1联合检测排除CT颅内损伤的敏感性0.91(95%CI 0.59-1.00),阴性预测值0.95(95%CI 0.76-1.00)。
  • 该检测特异性仅0.22(95%CI 0.14-0.31),阳性预测值0.12(95%CI 0.06-0.21),阳性结果不能确诊颅内损伤。
  • 假阳性病例中78%年龄大于真阴性病例(中位72岁 vs 58.5岁),老年人结果解读需谨慎。
  • GFAP/UCH-L1检测中位周转时间1.09小时,比头部CT的3.28小时快约2小时。
  • 作者结论:生物标志物可作CT前初始排除工具,但需大型多中心研究明确对急诊资源利用、住院时间和费用的影响。

适用人群与场景

  • 单中心纳入104例成人疑似轻型创伤性脑损伤患者,在I级创伤中心急诊接受头部CT评估,伤后12小时内采血。

诊断标准与关键阈值

  • 生物标志物阳性定义为GFAP >30 pg/mL或UCH-L1 >360 pg/mL。
  • 颅内损伤以头部CT识别为准。
  • 与加拿大头部CT规则(Canadian Head CT Rule)进行比较。

处置流程与药物剂量

  • 第一步:对疑似mTBI成人,伤后12小时内采外周血送医院临床实验室检测GFAP/UCH-L1。
  • 第二步:若GFAP >30 pg/mL或UCH-L1 >360 pg/mL,视为生物标志物阳性;结合临床决策规则决定是否行头部CT。
  • 第三步:生物标志物阴性(GFAP ≤30 pg/mL且UCH-L1 ≤360 pg/mL)时,阴性预测值0.95,可考虑作为CT前排除颅内损伤的参考,但原文未给出据此免行CT的具体推荐。

红旗征与不能漏的情况

  • 原文未提及需要立刻处理或不能漏诊的具体红旗征及对应处理。

研究设计与关键结果

  • 研究类型:单中心验证研究;样本量104例成人;单中心(I级创伤中心);人群为疑似mTBI并接受头部CT的急诊患者。
  • 干预:伤后12小时内采血检测GFAP/UCH-L1联合血浆试验;对照:加拿大头部CT规则。
  • 主要终点:预测CT颅内损伤的敏感性0.91(95%CI 0.59-1.00),特异性0.22(95%CI 0.14-0.31),阳性预测值0.12(95%CI 0.06-0.21),阴性预测值0.95(95%CI 0.76-1.00)。
  • 队列中83例生物标志物升高,11例CT发现颅内损伤。
  • 假阳性病例(78%)年龄大于真阴性病例(中位72岁 [IQR 54-83] vs 58.5岁 [IQR 38.25-66])。
  • GFAP/UCH-L1检测中位周转时间1.09小时(IQR 0.87-1.65),头部CT为3.28小时(IQR 2.37-4.70)。
  • 与既往研究一致:汇总敏感性0.97(95%CI 0.95-0.98),特异性0.28(95%CI 0.23-0.34)。

证据类型、等级与局限

  • 证据类型:单中心验证研究(非随机对照试验)。
  • 局限:单中心、样本量小(n=104)、假阳性率高、阳性预测值低;作者指出需大型多中心研究明确对急诊资源利用、住院时间和费用的影响。

对床旁实践的改变

  • 可考虑将GFAP/UCH-L1联合检测作为疑似mTBI成人CT前的初始排除工具,利用其高阴性预测值(0.95)辅助决策。
  • 因特异性低(0.22)和阳性预测值低(0.12),阳性结果不能替代CT诊断,仍需影像学确认。
  • 老年患者假阳性率更高(假阳性中位年龄72岁),结果解读时应考虑年龄因素。
  • 检测周转时间比CT快约2小时,可能有助于缩短急诊停留时间,但原文指出需多中心研究验证对资源利用和费用的影响。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

STUDY OBJECTIVE: Mild traumatic brain injury (mTBI) is a prevalent and resource-intensive injury in the emergency department (ED). The blood-based biomarkers glial fibrillary acidic protein (GFAP) and ubiquitin c-terminal hydrolase L1 (UCH-L1) have demonstrated diagnostic potential for acute structural brain injury. Our objective was to clinically validate a US Food and Drug Administration-approved plasma test to aid in the identification of intracranial injury in patients with mTBI presenting to the ED and assess its integration with existing protocols.

METHODS: This single-center validation study enrolled 104 adult patients with suspected mTBI undergoing head computed tomography (CT) for evaluation between October 2023 and June 2024 at a Level I trauma center. Peripheral blood draw was completed within 12 hours postinjury and processed at the hospital clinical laboratory. Sensitivity, specificity, and predictive values for the test were calculated and compared with a standard clinical decision rule (Canadian Head CT Rule). ED length of stay and diagnostic turnaround times were examined.

RESULTS: Within the cohort (n=104), 83 patients had elevated biomarker levels (GFAP >30 pg/mL or UCH-L1 >360 pg/mL), and 11 patients had intracranial injury identified on CT. The combination plasma test demonstrated high sensitivity (0.91 [95% confidence interval {CI} 0.59 to 1.00]) but low specificity (0.22 [95% CI 0.14 to 0.31]) for predicting intracranial injury on CT with low positive predictive value (0.12 [95% CI 0.06 to 0.21]) and high negative predictive value (0.95 [95% CI 0.76 to 1.00]). These findings are consistent with prior studies (pooled sensitivity 0.97 [95% CI 0.95 to 0.98]; specificity 0.28 [95% CI 0.23 to 0.34]). False-positive cases (78%) were older than true-negative cases (median 72 years [interquartile range (IQR) 54 to 83] versus 58.5 years [IQR 38.25 to 66]). Median turnaround time for the GFAP/UCH-L1 test was 2 hours faster than head CT (1.09 hours [IQR 0.87 to 1.65] versus 3.28 hours [IQR 2.37 to 4.70]).

CONCLUSIONS: Blood biomarkers for mTBI have potential as an initial rule-out tool for intracranial injury prior to obtaining CT imaging; however, large multicenter studies are needed to clarify its impact on ED resource utilization, length of stay, and acute and long-term costs and benefits to patients and health care systems.

来源:Ann Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Pandey S, Chen Y, Yue JK, et al. Associations Between Diagnostic Blood-Based Biomarkers and Neuroimaging Findings in Mild Traumatic Brain Injury. Ann Emerg Med. 2026. PMID: 42949696. doi:10.1016/j.annemergmed.2026.08.731

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。